Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

NCT07738887 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Ibrutinib Oral Tablet
DRUG: Venetoclax Oral Tablet
DRUG: Epcoritamab

Sponsor

The Lymphoma Academic Research Organisation

Collaborators

[object Object]
[object Object]
[object Object]